PepGen's CEO James McArthur gives an overview of the company's recent data in myotonic dystrophy type 1, which showed a mean splicing correction of 53.7% at the 15 mg/kg dose
- Oct 15, 2025
- 1 min read
He describes the science behind PepGen's "Enhanced Delivery Oligonucleotide (EDO)" platform, and explains how he believes it gives the company a differentiated advantage in this condition by focusing on the pathogenic repeat that causes DM1 and restoring normal function.
.png){kind=logo}